NY-SPRINKLR
8.12.2020 10:02:06 CET | Business Wire | Press release
Sprinklr , the Customer Experience Management (CXM) platform for modern enterprises, today announced that Nordea , the largest financial services group in Northern Europe, is expanding its use of Sprinklr to deliver digital, personalized banking experiences.
After replacing legacy systems with Sprinklr three years ago because it needed a scalable platform, Nordea has grown its partnership with Sprinklr and is now leveraging four Sprinklr products to create a collaborative, company-wide digital banking strategy.
The Challenge: Growing Company, Changing Customer Behavior & Siloed Reporting
Corporate growth combined with a substantial increase in digital engagement , undefined marketing goals, and disconnected teams created an opportunity for Nordea to develop a strategic digital vision with strong execution capabilities.
The Solution: A Company-Wide Digital Banking Strategy on Sprinklr
Nordea’s marketing team, customer service department, and agencies collaborate in one Sprinklr platform.
With Sprinklr Modern Advertising , Nordea has a single source of truth for agencies and in-house teams to view real-time ad reporting data.
With benchmarking in Sprinklr Modern Research , Nordea can understand where they stand compared to competitors across countries, and can track trending topics and themes in Swedish, Norwegian, Finnish, Danish, and English. Nordea also works with Sprinklr to improve sentiment tracking for Nordic languages.
With Sprinklr Modern Care , the company has dramatically improved the efficiency of their support team. Nordea can use Sprinklr to easily understand if customers are asking questions about specific services – such as a business loan – and quickly connect them to the relevant care agent.
With Sprinklr Modern Engagement , Nordea has one content calendar to collaborate, publish, and plan marketing and engagement campaigns across Twitter, Facebook, Instagram, LinkedIn, and YouTube and answer inquiries on Google My Business and Trustpilot.
Comments on the News:
“Nordea is committed to being the bank of the future that our customers need,” said Elizabeth Fjellerup, Group CMO at Nordea. “Sprinklr provides us with a single platform to enhance every customer experience while empowering our teams to work together with the insights they need to make smart decisions.”
“Nordea is driving digital transformation forward within the financial services industry,” said Pavitar Singh, Chief Technology Officer, Sprinklr. “By implementing a single, companywide Sprinklr platform, Nordea has a clear understanding of its marketing and customer service performance along with deep customer insight. We’re proud to support Nordea’s commitment to delivering an easy digital banking experience.”
Additional Resources:
- Request a Sprinklr demo .
- Read Sprinklr Customer Stories .
About Sprinklr
Sprinklr (@Sprinklr ) is the world’s leading Customer Experience Management (CXM) platform. We help organizations reach, engage and listen to customers across 26 social channels, 11 messaging channels, and hundreds of millions of forums, blogs, and review sites. Sprinklr is a global company with 1,900 employees helping the world’s most valuable enterprises make their customers happier.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005160/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
